Safety of Tiotropium Prescription in Chronic Obstructive Pulmonary Disease (COPD): A survey in patients taking Tiotropium at the time of an admission to hospital with an Acute Exacerbation of COPD.

In patients with COPD, what are the patterns of use of Tiotropium at the time of an admission to hospital.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12615000492550

Enrollment

100

Registered

2015-05-19

Start date

2015-05-21

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The study aims to collect information about inhaler use in patients who are prescribed a tiotropium inhaler (Spiriva). This medication in commonly prescribed in chronic obstructive pulmonary disease (COPD) but it is unclear how patients are using this medication at home. The study involves the idetification of patients admitted to hospital for an exacerbation of COPD who are prescribed Spiriva at the time of admission. These patients will be approached to complete a questionnaire which collects data about their usual use of this medication as well as their use in the 7 day period prior to hospital admission. If they are prescribed a similar medication called ipratropium as well as Spiriva, they will be asked to complete an additional questionnaire. The data collected will help to identify if patients are using the Spiriva inhaler as prescribed by their doctor, if they are taking more than the prescribed dose and whether they are prescribed another similar medication at the same time as taking Spiriva (ipratropium).

Interventions

Eligible participants with Chronic Obstructive Pulmonary Disease (COPD) will be given questionnaire(s) to complete relating to the specific medications that they are prescribed. Each participant will complete a questionnaire relating to Tiotropium use. Tiotropium is a Long-Acting Muscarinic Antagonist (LAMA) inhaler used in patients with COPD. It should not be co-prescribed with Short-Acting Muscarinic Antagonists (such as Ipratropium) due to unwanted side-effects and cardiovascular risks. If participants are prescribed concomitant ipratropium-containing medications they will receive an additional questionnaire for each of these medications. The duration of observation in each participant will be as long as is required for the participant to fill out the questionnaire(s), and is anticipated to take no longer than thirty minutes.

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

i. Admitted to hospital with an AECOPD. ii. Prescribed Tiotropium at the time of admission. iii. Greater than or equal to 40 years of age on admission

Exclusion criteria

i. Patients unwilling to complete the questionnaire(s). ii. Patients in whom Tiotropium has been commenced during this admission. iii. Patients who do not have the capacity to give full written informed consent to participate in the study (as judged by the investigator).

Outcome results